Dean&Francis
ISSN 2959-409X

Current Situation of 3D Bio-printing Technology

Haoqian Zhou[1, *]

[1]Canadian International School GuangZhou, GuangZhou, 511400, China
*Corresponding author: haoqianzhou0522@gmail.com

Abstract:

To create functional tissues and probably fully functional human tissues, 3D bioprinting is a new technology that combines the efficiency of additive manufacturing with the difficulty of living techniques. Bioprinters can produce patient-specific constructs that resemble local cell structures and function using bio-inks made of living cells, biomaterials, and chemical cues. This paper provides a complete overview of the field, tracing its evolution from first scaffold-based approaches in the 1980s to breakthroughs such as AI-helped design, intraoperative bioprinting, and space-based tissue maturation. Regenerative medicine, disease modeling, pharmaceutical testing, aesthetic analysis, and cultured meat generation are just a few examples of the latest software. Despite these advances, challenges remain in achieving total vascularization, ensuring long-term cell viability, overcoming materials limitations, and addressing social and regulatory considerations. The paper also discusses potential directions, including on-demand tissue printing, global availability initiatives, and the integration of bioprinting with other renewable therapies. 3D bioprinting has the potential to revolutionize medicine and business by fostering cross-disciplinary collaboration and creativity, reducing the need for pet testing, and opening up new frontiers in both space and earth environments.

Keywords: 3D bioprinting; Healthcare; Industry.

1. Introduction

One of the most interesting and revolutionary developments in biomedical engineering is 3D bioprinting. It enables scientists to create functional tissues and, in the near future, potentially even whole organs by combining the perfection of additive manufacturing with the natural richness of living techniques [1]. Bioprinting uses specifically formulated bio-inks, unlike standard additive manufacturing, which relies on insoluble materials like metal, ceramics, and polymers. These bio-inks are special blends of living tissues, biomaterials, and signaling substances that are layer by layer deposited to build structures that resemble local tissues‘ natural functions and architecture.

Over the past ten years, and for good reason, interest in this field has grown exponentially. Every season, there are thousands of preventable deaths due to the global shortfall of recipient tissues. In contrast, drug development continues to be slower, cheaper, and heavily reliant on animal models, which frequently fail to account for how well a drug will fare in humans [2]. 3D bioprinting had significantly lower transplant rejection rates, accelerate-dincreased medical research, and ledled to the development of novel regenerative therapies that were previously thought impossible.

Other options include, but are not limited to, nursing. To morally check products, quickly develop natural prototypes, and create sustainably raised meat from labs, cosmetic companies, medical developers, and even the food industry are considering bioprinting. The ability to print anything from easy, smooth cell layers to intricate vascularized structures is what makes the technology so fascinating.

This document aims to provide a comprehensive overview of 3D bioprinting, including where it came from, how it works, the materials used to make it possible, how it is already being used, and the remaining obstacles. It also examines potential applications for the upcoming century, including advances in bio-ink chemistry, growing requirements, and potential connections between AI and space research.

2. 3D bioprinting's history and development

2.1 First Origins: 1980s–1990s

The wider area of additive manufacturing is where the story of 3D bioprinting begins. Using ultraviolet light to cure plastics, Charles Hull created stereolithography, a technique that allowed things to be created layer by layer from a digital model in 1984 [1]. This was originally intended for rapid development in industries like aerospace and automotive production.

Biomedical engineers were beginning to be inspired by advances in computer-aided design (CAD) and material science by the late 1980s and early 1990s. Had life cells been constructed using the same rules? Researchers experimented with biodegradable polymer scaffolds made of polylactic acid (PLA) and polyglycolic acid (PGA), but early efforts didn't yet involve living cells. This scaffolding may support the growth of new cells once they have been seeded with tissue.

The development of tissue engineering as a control coincided with this time. The concept of combining living cells with materials to repair or replace broken tissues was first proposed in Langer and Vacanti's important evaluation in 1993. An entire century of regenerative medicine researchers would continue to be inspired by their function.

2.2 First natural prints from 2000 to 2005

A real turning point occurred in the early 2000s. A University of Missouri group modified a traditional jet printer in 2003 to accurately loan life mammalian cells without causing any harm in the process [3]. This discovery opened the door for the contemporary period of bioprinting and demonstrated that existing printing techniques may be adapted for sensitive natural materials.

Practical kidney tissue was engineered and successfully implanted into individuals by Dr. Anthony Atala's Wake Forest Institute for Regenerative Medicine around the same time [3]. One of the first clinical trials of engineered cells to demonstrate the compatibility of body publishing and scaffold-based methods.

Boland and Albert (2004) expanded by publishing two distinct cell types in a single cell. This demonstrated the ability to print tissues that behave like true things by printing difficult, multicellular tissue designs.

2.3 Monetization from 2009 to 2015

With Organovo's foundation in 2009, the industrialization of 3D bioprinting took off. The company's primary objective for drug discovery and disease modeling was practical people cell. It released its first three-dimensional heart muscle for poisoning testing, which could work for weeks in vitro by 2013 [3].

L'Oréal, a major cosmetics company, collaborated with Organovo 2015 to create biomimetic animal skin for product testing [4]. Moving away from animal testing, the goal was to develop human-compatible body designs that could represent a range of ages, ethnicities, and problems.

Academic laboratories were rapidly evolving at the same time. Squads at Harvard, MIT made advancements in multi-material printing, vascularization methods, stem-cell-based bio-inks, and the University of Wollongong, further increasing what was possible

2.4 Development and expansion: 2016-2020

The industry experienced swift technological maturation between 2016 and 2020. Multi-material and multi-cell publishing became more prevalent, enabling the development of tissues with multiple practical layers [2]. Organ-on-a-chip technology, combining biomaterial cells with microfluidic systems, started to create real tissue biology accurately, including blood flow and waste removal [2].

ISSN 2959-409X

Vascularization was a key study area because endothelial cells were used to create microchannel systems mimicking basic heart vessels. A breakthrough for organ simulation was printed in 2019 by researchers at Tel Aviv University, making it possible to model a tiny but biologically appropriate center complete with cells, blood vessels, ventricles, and chambers.

2.5 Latest Advancements: 2021-2025

2022: The first patient-specific, bioprinted ear implant clinical trial was conducted using the patient‘s cartilage cells .
2023: NASA expanded its bioprinting experiments aboard the International Space Station, examining how cells mature in microgravity.
2024: Intraoperative bioprinting entered clinical trials, letting surgeons display muscle straight into a wound during the middle of an operation.
2025: AI-powered design efficiency began integrating the process, accelerating printing speeds, improving accuracy, and predicting long-term tissue behavior [5,6].

3. 3D Bioprinting Technology

3.1 General Printing Process

A detailed description of the specific tissue or organ is the first step in any 3D bioprinting task. This is often created by applying high-quality imaging methods such as CT scans or MRI [1]. The model is then divided into thin digital layers using computer-aided design (CAD) software. The printer then perfectly adheres to these pieces, putting bio-ink in barren and meticulous economic problems to achieve the best battery survival rates [2].
More than just stacking substance, the architecture of a living structure is involved. How well the tissue survives the cartridge-to-be-configured process can be greatly impacted by temperature, humidity, and the pressure inside the tip. Achieving a successful print requires a balance between natural functionality and electrical stability.

3.2 Bio-Ink Materials

The center of biomaterial technology is bio-inks, which are both physically and medically compatible.
Collagen, gelatin, bentonite, fibrin, and other natural polymers closely resemble the body‘s extracellular matrix, which promotes cell adhesion and growth [6]. In addition to providing structural support, synthetic polymers like polyethylene glycol (PEG) and polycaprolactone (PCL) have superior mechanical strength and slower degradation rates [7,8]. Hybrid bio-inks combine the best of both worlds by combining natural and synthetic components for optimal printability, cell compatibility, and durability. The „perfect“ bio-ink must protect cells from harmful strain forces, offer nutrients, and provide the appropriate chemical cues to mature those cells into practical tissue [9].

3.3 Printing Methods

There are various printing methods, each with its own advantages and disadvantages:high-speed printing is possible with tiny drops of low-viscosity bio-inks in inkjet bioprinting, but it struggles to create strong, large-scale buildings. Even though the electrical tension of the filament is lower, cell viability, thicker, more fluid paints, and larger builds are used for extrusion bioprinting. Despite having incredibly high quality and cell viability, laser-aided biomaterial requires expensive and challenging products. The best method is used depending on the type of muscle being printed, the bio-ink development used, and the program being used.

3.4 Organ-on-a-Chip Integration

Incorporating biomimetic cells into micro products, commonly called „organ on a device“ systems, is a particularly interesting development [2]. These cards can create structural forces like strength contractions, nutritional trade, and blood circulation. Organ-on-chip models are becoming valuable resources for learning disease progression and developing new drugs because they combine the authenticity of living cells with exact control over the environment.

4. Applications of 3D Bioprinting

3D bioprinting is impacting fields as diverse as space exploration and regenerative medicine.

4.1 Regenerative Medicine

Regenerative medicine is one of the most interesting areas where biomaterials are starting to take off. Here, the objective is to create patient-specific transplants and implants capable of replacing or repairing damaged cells. For instance, scientists are developing biomimetic skin grafts made of layers of cells and keratinocytes to treat severe burns. These implants are intended to blend effortlessly with a patient‘s individual skin, providing a safer and more personal alternative to traditional transplanting methods [6]. In people with knee injuries or osteoporosis, chondrocyte-seeded scaffolding is being tested for tissue repair, and they show encouraging signs of cell rejuvenation over time. Because they provide both the structural support needed for bone treatment and the natural signs

that promote new growth, PCL-based scaffold loaded with stem cells has proved particularly useful in renal restoration [7]. These examples demonstrate how biomaterials are rapidly moving from a concept to a clinic, offering natural and mechanical solutions.

4.2 Research and Industrial Applications

Beyond simple health procedures, bioprinting is possible. Scientists have already used biomimetic mini-organs to study how cells work and how diseases develop [10]. For example, small heart models are assisting in predicting how new drugs may be metabolized and whether they may have harmful side effects before human trials start. Providing physicians a powerful tool for personalized drug testing and treatment planning, patients particular organs can even be printed to imitate an individual‘s special disease profile, whether it‘s cancer, fibrosis, or another state [9]. Additionally, this study is hardly limited to Earth. NASA has effectively bioprinted bone and lined cells aboard the International Space Station, using microgravity to examine how cells adapt in space and paving the way for advances in astronaut health and long-term space travel.

Bioprinting has furthermore gained acceptance in business. To avoid animal testing and better understand how merchandise interacts with various skin types, cosmetic companies like L‘Oréal have already started using branded body types [11]. However, the food market is exploring bioprinting to make cultured meat, producing lab-grown cuts that closely match regular meat in taste and texture but with far less economic impact. In the near future, commercial applications could expand to include everything from personal makeup and biomaterials to high-throughput drug testing platforms. These innovations demonstrate how flexible biomaterials have become, bridging the gap between medical needs and laboratory research.

5. Obstacles in 3D Bioprinting

Despite amazing advancements, substantial obstacles must be overcome before 3D bioprinting can realize its full potential. Thick, functional tissues need body vessels for nourishment and oxygen [8,9]. Scientists are experimenting with publishing microchannels, including endothelial cells to promote vehicle development, and dissolving ceremonial bio-inks to create hollow channels. On the other hand, no present approach can match the difficulty and effectiveness of natural vascular systems.

Structural stress can cause damage to cells during printing [6]. Although changing nozzle dimensions, pressures, and temperatures may be helpful, published cells also require the appropriate chemical signals to develop into fully functional cells. Additionally, artificial polymers are solid but medically inert, whereas organic polymers are physically weak but biocompatible [7]. Cross-paints fix some problems, but they can complicate the publishing process. The immune system may reject printed organs if they aren‘t made from the patient‘s cells [8]. Using induced pluripotent stem cells (iPSCs) from the patient or using immune-modulatory coatings are possible options. Sophisticated organs can take hours or days to write, while bioprinters and barren facilities are costly. For common adoption, it is essential to shorten write times and increase flexibility. Additionally, recommendations for biomaterial products are still being developed by governmental bodies like the FDA and EMA [6,12]. Additionally, ethical issues arise regarding fair entry, informed consent for mobile purchasing, and preventing misuse for non-therapeutic improvements.

6. Instructions in the Future

3D bioprinting from research laboratories might become widely used in medical applications in the coming century. Institutions may one day display patient-specific tissues on site, ending instrument shortages, with advances in vascularization and multi-material printing. For better function, AI is fine-tuning bio-ink formulations, printing parameters, and architectural designs [9,7]. Before printing the second part, simulations can forecast long-term efficiency. Complex tissues like heart muscle with integrated vessels and electronic pathways, or skin with all its layers, are made possible by printing various cell types in a single development. Developing gentle, complex cells that are challenging to produce on Earth may be made in microgravity [5]. These could be repurposed for research in orbit or for medical purposes. Low- and middle-income countries could benefit from open-source bio-ink recipes and low-cost printers, reducing care disparities. Gene treatment, CRISPR, and cutting-edge stem cell therapies may be combined with biomaterials to create truly personalized regenerative medicine for conditions previously deemed intractable.

7. Conclusion

A potential where developing functional tissues and even whole organs may become a regular medical treatment is possible thanks to 3D bioprinting, which is at the crossing of engineering innovation and natural complexity. The industry has changed from printing straightforward polymer scaffolds to creating complex structures based on genuine tissue functions and vascular networks. Its software extends beyond regenerative medicine, influencing medical

ISSN 2959-409X

studies, cosmetic testing, food systems, and space exploration.

However, the road to fully useful, transplant-ready tissues is incomplete. Innovative options are also needed to overcome technical obstacles like vascularization, cell viability, and material limits. To maintain a healthy, equitable, and responsible usage of technology, ethical and regulatory frameworks must also keep up with technological advancements.

Advancements could be accelerated by integrating advanced bio-ink chemistry, space-based research, and artificial intelligence in ways we can‘t even imagine now. In the twenty-first century, 3D bioprinting has the potential to alter how individuals think about life, health, and conservation with ongoing global cooperation and a commitment to convenience.

References

[1] Heinrich, M.A., Liu, W., Jimenez, A., et al. 3D Bioprinting: from Benches to Translational Applications. Small, 15(23), 1805510. Wiley, 2019.

[2] Yu, C., Ma, X., Zhu, W., et al. Current Advances in 3D Bioprinting Technology and Its Applications for Tissue Engineering. Polymers, 12(12), 2958. MDPI, 2020.

[3] Opentextbooks Clemson. Bioprinting: History and Developments. Open Textbooks, Clemson University, 2020.

[4] Wired. L’Oréal Partners with Organovo to 3D Print Skin. Wired, 2015.

[5] NASA. 3D Bioprinting aboard the International Space Station. NASA, 2023.

[6] U.S. Food and Drug Administration (FDA). 3D Bioprinting and Bio-Ink Regulation. FDA, 2021.

[7] National Institutes of Health (NIH). Synthetic Polymers in Bioprinting. NIH, 2023.

[8] U.S. National Library of Medicine. Hybrid Bio-Inks and Stem Cell Applications. NLM, 2023.

[9] World Health Organization (WHO). Emerging Technologies: 3D Bioprinting. WHO, 2023.

[10] Merck. Advances in 3D Bioprinted Liver Models. Merck, 2022.

[11] L’Oréal. Ethical Testing with 3D Printed Skin. L’Oréal, 2020.

[12] U.S. Food and Drug Administration (FDA). Guidance on 3D Bioprinted Medical Products. FDA, 2022.